SYRE
Spyre Therapeutics Inc.
$73.65
-$0.40(-0.54%)
49
Overall
60
Value
66
Tech
21
Quality
Market Cap
$1.65B
Volume
478.43K
52W Range
$13.93 - $76.00
Target Price
$95.20
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $4.6M | $5.2M | $3.9M | -- | -- | $18.7M | $2.3M | $886.0K | -- | -- | ||
| Total Revenue | $4.6M | $5.2M | $3.9M | -- | -- | $18.7M | $2.3M | $886.0K | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $4.6M | $5.2M | $3.9M | -- | -- | $18.7M | $2.3M | $886.0K | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-26.5M | $-32.9M | $49.4M | $80.3M | $81.5M | $84.4M | $87.1M | $243.2M | $208.6M | $209.6M | ||
| Research & Development | $18.1M | $22.8M | $36.7M | $64.6M | $59.6M | $57.1M | $58.6M | $89.5M | $162.8M | $171.7M | ||
| Research Expense | $18.1M | $22.8M | $36.7M | $64.6M | $59.6M | $57.1M | $58.6M | $89.5M | $162.8M | $171.7M | ||
| Selling, General & Administrative | $8.4M | $10.1M | $12.6M | $15.7M | $21.8M | $27.3M | $28.5M | $39.9M | $45.8M | $47.9M | ||
| General & Administrative Expenses | $8.4M | $10.1M | $12.6M | $15.7M | $21.8M | $27.3M | $28.5M | $39.9M | $45.8M | $47.9M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | -- | -- | $25.7M | $44.8M | $37.6M | ||
| Depreciation & Amortization | $-132.0K | $-249.0K | $-293.0K | $400.0K | $996.0K | $1.6M | $1.6M | $744.0K | -- | -- | ||
| Depreciation & Amortization | $-132.0K | $-249.0K | $-293.0K | $400.0K | $996.0K | $1.6M | $1.6M | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $1.3M | $1.9M | $1.5M | $1.4M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-21.9M | $-27.7M | $-45.5M | $-80.3M | $-81.5M | $-65.6M | $-84.8M | $-242.3M | $-208.6M | $-209.6M | ||
| EBITDA | $-21.5M | $-27.0M | $-44.6M | $-78.7M | $-80.5M | $-64.1M | $-82.0M | $-354.3M | $-208.0M | $-165.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | -- | -- | -- | -- | -- | -- | -- | -- | $21.3M | -- | ||
| Net Non-Operating Interest Income/Expense | $244.0K | $482.0K | $1.2M | -- | -- | -- | $-837.0K | $-6.1M | $21.3M | -- | ||
| Gain on Sale of Securities | -- | -- | -- | $2.1M | $593.0K | $111.0K | $837.0K | $6.1M | $21.3M | $24.9M | ||
| Other Income/Expense | $36.0K | $42.0K | $57.0K | $-2.1M | $-588.0K | $11.0K | $-7.0K | $13.0M | $-599.0K | $-54.3M | ||
| Other Special Charges | $-36.0K | $-42.0K | $-57.0K | $-63.0K | $-5.0K | $-122.0K | $-7.0K | $-19.1M | $-20.7M | $29.5M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | $-6.4M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-21.7M | $-27.2M | $-44.3M | $-78.3M | $-81.5M | $-65.6M | $-84.0M | $-355.3M | $-208.0M | $-165.2M | ||
| Pre-Tax Income | $-21.7M | $-27.2M | $-44.3M | $-78.3M | $-80.9M | $-65.7M | $-84.0M | $-338.8M | $-208.0M | $-155.2M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-333.0K | $-296.0K | $-264.0K | $-98.0K | -- | $141.0K | $-136.0K | $-26.0K | $51.0K | $-15.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-21.7M | $-27.2M | $-44.3M | $-78.3M | $-80.9M | $-65.8M | $-83.8M | $-338.8M | $-208.0M | $-155.2M | ||
| Net Income (Continuing Operations) | $-21.7M | $-27.2M | $-44.3M | $-78.3M | $-80.9M | $-65.8M | $-83.8M | $-355.2M | $-208.0M | $-165.2M | ||
| Net Income (Discontinued Operations) | $-21.7M | $-27.2M | $-44.3M | $-78.3M | $-80.9M | $-65.8M | $-83.8M | $-338.8M | $-208.0M | $-155.2M | ||
| Net Income (Common Stockholders) | $-21.7M | $-27.2M | $-44.3M | $-78.3M | $-80.9M | $-65.8M | $-83.8M | $-338.8M | $-208.0M | $-155.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-155.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-26.5M | $-32.9M | $49.4M | $80.3M | $81.5M | $84.4M | $87.1M | $243.2M | $208.6M | $209.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $391.7K | $605.1K | $832.9K | $1.3M | $2.1M | $2.6M | $3.4M | $6.9M | -- | -- | ||
| Average Shares Outstanding (Diluted) | $391.0K | $605.2K | $832.9K | $1.3M | $2.1M | -- | $3.4M | $6.9M | $73.0M | -- | ||
| Shares Outstanding | $538.1K | $668.7K | $1.2M | $1.2M | $1.9M | $2.0M | $2.6M | $36.2M | $60.3M | $78.5M | ||
| Basic EPS | -- | -- | -- | $-61.25 | $-38 | $-25 | $-24.75 | $-49.12 | -- | $-1.98 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-61.25 | $-38 | $-25 | $-24.75 | $-49.12 | -- | -- | ||
| Diluted EPS | $-55.5 | $-45 | $-53.25 | $-61.25 | $-38 | $-25 | $-24.75 | $-49.12 | -- | -- | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-53.25 | -- | -- | -- | $-24.75 | $-49.12 | -- | -- | ||
| OTHER METRICS | ||||||||||||
| Earnings from equity interest | -- | -- | -- | -- | $-80.9M | $-65.7M | $-84.0M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | $-80.9M | $-65.7M | $-84.0M | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | -- | -- | -- | $16.4M | -- | $10.0M | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | $16.4M | -- | $10.0M | ||
| Other Gand A | $8.4M | $10.1M | $12.6M | $15.7M | $21.8M | $27.3M | $28.5M | $39.9M | $45.8M | $47.9M | ||
| Rent And Landing Fees | $8.4M | $10.1M | $-400.0K | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SYRE | $73.65 | -0.5% | 478.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |